Biotechnology

Moderna's fair value estimate has been lifted from US$119.56 to US$122.67 per share, according to updated modelling tied to analyst revisions on its intismeran cancer vaccine program. The change follows Phase 3 INTerpath-001 melanoma data that prompted target lifts or upgrades from BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley, with BofA setting a US$200 target and a Neutral rating and calling the readout a watershed moment for Moderna. William Blair moved to Outperform and Wolfe Research called the melanoma result de-risking for the broader intismeran platform, while RBC Capital described the data as a massive scientific breakthrough. On the bearish side, Citi and Rothschild & Co Redburn moved to Sell even as they raised targets to US$80 and US$81 respectively, citing questions on oncology revenue expectations and limited disclosure around efficacy metrics such as hazard ratios. The updated model also shifted the revenue growth assumption from 26.74% to 26.75%, the net profit margin from 17.25% to 17.20%, the future P/E from 80.90x to 83.10x, and the discount rate from 7.50% to 7.46%.

Hybribio announced on October 11 that its wholly-owned subsidiary, Chaozhou Hybribio Biochemistry Co., Ltd., has recently obtained the Medical Device Registration Certificate of the People's Republic of China for in vitro diagnostic reagents issued by the National Medical Products Administration. The registered product is a vaginal microorganism nucleic acid detection kit using PCR-fluorescent probe method, valid from October 9, 2026 to October 8, 2031, primarily for the in vitro qualitative detection of nucleic acids of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans in vaginal secretions. The company stated that obtaining this registration certificate will further improve its product portfolio for reproductive tract infection testing, meet diversified market demand, and support its goal of becoming a leading enterprise in nucleic acid molecular diagnostics. The announcement also cautioned that actual sales and profit contribution of the approved product are subject to factors such as market promotion effectiveness and actual demand, and remain uncertain; the company is currently unable to predict the impact on its future operating results. In the interim period of 2026, Hybribio achieved revenue of 300 million yuan and net profit attributable to the parent company of 31.26 million yuan.

Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.

Baili Tianheng announced on October 11 that the company recently received the official approval of the Drug Clinical Trial Approval Notice from the National Medical Products Administration. Its self-developed, first-in-class drug Izabren (luncombe izabren, BL-B01D1/iza-bren) combined with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved for clinical trials. The announcement stated that Izabren is the world's first and only approved EGFR×HER3 bispecific antibody-drug conjugate, and has currently initiated more than 45 clinical trials for multiple tumor types in China and the United States, including 20 Phase III clinical studies (including Phase II/III). Izabren has 9 indications included in the National Medical Products Administration's Center for Drug Evaluation breakthrough therapy designation list, 2 indications included in the priority review designation list, and some indications have also received marketing approval from the National Medical Products Administration. In mid-2026, Baili Tianheng achieved revenue of 0.0 yuan and a net loss attributable to the parent company of 1.637 billion yuan.

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

vTv Therapeutics announced that Chief Medical Officer Thomas Strack presented new research on hypoglycemia-related burdens among adults with type 1 diabetes using automated insulin delivery systems at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia. The study, commissioned by vTv and conducted by dQ&A Market Research, surveyed 674 adults with type 1 diabetes, of whom 429 were using automated insulin delivery systems. Among those AID users, 24% reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia. After accounting for overlap across segments and weighting for A1C, approximately 54% of adults with type 1 diabetes using an AID system were estimated to experience at least one of four hypoglycemia-related burden dimensions. The research supports vTv's cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator being evaluated as an adjunctive therapy to insulin for type 1 diabetes, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.

AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal cancer and non small cell lung cancer. The designations apply to biomarker defined patient groups in those two large solid tumor indications, and they mark the first Breakthrough Therapy status for telisotuzumab adizutecan, which sits in AbbVie's antibody drug conjugate pipeline. Colorectal cancer and non small cell lung cancer together affect more than four million people worldwide each year, and the focus on biomarker defined groups, including c Met protein expressing NSCLC, points to narrower patient pools but potentially higher value treatment settings. The designations support the view that AbbVie needs its pipeline to replace aging blockbusters such as Humira and Imbruvica, with telisotuzumab adizutecan complementing oncology assets like etentamig. The next signpost is how the ongoing Phase 3 and Phase 2/3 telisotuzumab adizutecan studies progress and when AbbVie moves toward regulatory filings in colorectal cancer and non small cell lung cancer, building on the first in human M21 404 data.

3SBio subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng have signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials. The deal lands as 3SBio shares trade at HK$15.07, with a 1-year total shareholder return down 45.58 percent, a 30-day share price return down 6.69 percent and a year-to-date share price return down 38.69 percent, even as the 3-year total shareholder return is up more than 2x. On valuation, 3SBio trades at a P/E of 3.9x against a Hong Kong Biotechs industry average of 17.3x and a peer group average of 36.2x, with an estimated fair P/E of 8.2x. A discounted cash flow model puts 3SBio's estimated future cash flow value at HK$33.62 versus the current HK$15.07 share price. Recent declines in revenue and net income, combined with the weak 1-year return, could pressure sentiment if MDR-001 progress disappoints.

Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant perioperative treatment of resectable microsatellite instability-high or mismatch repair-deficient colon cancer. The trial, designated COMPASSION-40/AK104-313, marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and is the 13th Phase III or registrational study of the therapy conducted globally. Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, and patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%. No immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer. Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in MSI-H/dMMR colorectal cancer, where data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response rate of 84.6% and a major pathological response rate of 100% among patients who proceeded to surgery, with a manageable safety profile.

The U.S. Food and Drug Administration granted Breakthrough Device designation to Natera's blood-based multi-cancer early detection assay, sending shares of the genetic testing company up 1.7% in the morning session. The regulatory decision followed the agency's evaluation of performance data spanning 12 cancer types, assessing the assay's sensitivity, specificity, and cancer signal origin performance. The FDA Breakthrough Devices Program is designed to expedite the development and review of medical devices that diagnose or treat life-threatening conditions. Natera shares were trading at $400.22, up 2.2% from the previous close, and the stock is up 74.9% since the beginning of the year. The move comes 17 days after the stock gained 5.2% on news that Japan's Pharmaceuticals and Medical Devices Agency granted regulatory approval for its Signatera test as a companion diagnostic in muscle-invasive bladder cancer, with a commercial launch in Japan planned for the first half of 2027.

Shares of Moderna and Novavax rose today after The New York Times reported that the US National Institutes of Health, or NIH, plans to launch a public-private partnership to accelerate the development of personalized cancer vaccines. The vaccine project is expected to begin in December, focusing on pancreatic cancer, liver cancer, and colorectal cancer, as well as certain tumors in children. Previous trials have used mRNA technology to train the body's immune system to recognize and attack proteins specific to cancer cells. The positive reaction to the news was most evident for Moderna, which is developing personalized mRNA cancer vaccines together with Merck. Moderna's share price has soared more than 600% since the start of this year, making it the best-performing stock among the companies used to calculate the S&P 500 index.

Vertex Pharmaceuticals announced new interim data showing that ALYFTREK, or vanzacaftor/tezacaftor/deutivacaftor, restored exocrine pancreatic function in some children with cystic fibrosis ages 2 to 5, allowing them to stop pancreatic enzyme replacement therapy. The data, presented as a late breaker poster at the North American Cystic Fibrosis Conference, came from 48 children enrolled in the PERT discontinuation substudy VX22-121-106 Cohort 2, part of an ongoing open-label extension study in that age group. After at least 48 weeks of treatment, mean fecal elastase-1 was 239.7 micrograms per gram, a mean increase of 110.2 micrograms per gram from baseline, and 48.6 percent of children reached the pancreatic sufficiency threshold of at least 200 micrograms per gram. Of the 48 children eligible for the substudy, 18, or 37.5 percent, successfully discontinued pancreatic enzyme replacement therapy for a mean duration of 8.6 weeks, and across the full enrolled cohort of 66 children, 50 percent were not on the therapy at the data cut. Carmen Bozic, Vertex's chief medical officer, said the findings represent a profound shift in understanding the benefits of treating cystic fibrosis in its earliest stages, noting that pancreatic failure had long been considered irreversible. Vertex also presented additional abstracts at the conference, held October 7 to 10 in Atlanta, on clinical and real-world evidence for CFTR modulators, including a post-hoc analysis of reduced intravenous antibiotic use with VNZ/TEZ/D-IVA in patients 12 and older and a natural history study of exocrine pancreatic function in infants under 12 months. The use of ALYFTREK in children 2 to 5 years old is investigational.

WallachBeth Capital announced that bioAffinity Technologies has closed a registered direct offering of common stock to an institutional investor at $6.122 per share, or $6.115 per pre-funded warrant, priced at-the-market under Nasdaq rules. The gross proceeds to the company were approximately $4 million before deducting placement agent fees and other offering expenses. In a concurrent private placement, bioAffinity also closed warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share, with the pre-funded warrants carrying an exercise price of $0.007 per share; both sets of warrants become exercisable following stockholder approval and expire five years from that approval. WallachBeth Capital acted as sole placement agent for the offering. bioAffinity, a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, intends to use the net proceeds for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and general corporate purposes.

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to accelerate cancer vaccine development, with investors seeing the mRNA biotech company in particular as a beneficiary. Other pharmaceutical stocks, including Pfizer, BioNTech, and Merck, also rose. According to the New York Times, the new initiative is a public-private partnership, similar to the effort that produced COVID-19 vaccines, that involves the National Institutes of Health, the NIH's nonprofit arm, researchers, pharmaceutical and biotech companies, advocacy groups, other nonprofits, and patients. Stacey Adam, a senior clinical officer at the NIH's foundation, told the New York Times that she expects the program to launch in December, and in 2024 the UK launched a similar program called the Cancer Vaccine Launch Pad. Moderna is viewed as a leader in mRNA cancer treatments, and the stock soared in August on positive results for a melanoma treatment developed with Merck; year to date, Moderna stock is up 627%.

bioAffinity Technologies has closed a registered direct offering of common stock to an institutional investor at $6.122 per share, or $6.115 per pre-funded warrant, priced at-the-market under Nasdaq rules, alongside a concurrent private placement of warrants. The private placement covers warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share, while the pre-funded warrants carry an exercise price of $0.007 per share; both sets of warrants become exercisable following stockholder approval and expire five years from that approval. Gross proceeds from the offering totaled approximately $4 million before deducting placement agent fees and other offering expenses, with WallachBeth Capital, LLC serving as sole placement agent. bioAffinity said it intends to use the net proceeds for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and for general corporate purposes. The common stock was offered under a shelf registration statement on Form S-3, File No. 333-275608, declared effective by the SEC on November 27, 2023.

AbbVie grew total revenue 10.2% to $16.99 billion last quarter even as Humira sales fell 35.9% to $756 million, with the company's newer immunology drugs carrying the growth. Skyrizi brought in $5.505 billion, up 24.4%, and Rinvoq added $2.525 billion, up 24.5%, lifting total immunology sales to $8.786 billion, up 15.1%. Neuroscience contributed $3.228 billion, up 20.3%, while oncology slipped 1.5% to $1.650 billion and aesthetics edged up 0.3% to $1.282 billion. Adjusted earnings per share came in at $3.65, up 22.9%, against GAAP earnings of $2.03, and management guides to full-year adjusted EPS of $13.87 to $14.07. AbbVie recently closed its purchase of Apogee Therapeutics at $135.11 per share in cash, for a total equity value of $10.9 billion, a deal the company says will reduce adjusted EPS by $0.14 this year and approximately $0.46 in 2027, with accretion beginning in 2032. At a forward P/E of 18.97 as of October 6, AbbVie trades essentially in line with the sector's 18.84 but above its own five-year average of 14.51, a premium that leans on expected EPS growth of 16.14% in 2027.

Intellia Therapeutics shares rallied 7.6% in the last trading session to close at $12.6, a move that appears to reflect growing investor confidence in the company's regulatory progress and financial position. The FDA accepted the biologics license application for lonvoguran ziclumeran, or lonvo-z, Intellia's investigational CRISPR-based treatment for hereditary angioedema, under Priority Review with a March 10, 2027 decision date. The company also secured an OrbiMed debt facility of up to $400 million in September, including $75 million upfront, to help support development and potential commercialization. Intellia is expected to post a quarterly loss of $0.82 per share in its upcoming report, a year-over-year change of +10.9%, on revenues of $10 million, down 27.5% from the year-ago quarter, while the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. The stock currently carries a Zacks Rank #3 (Hold).

MicuRx Pharmaceuticals has signed an exclusive license agreement and a platform technology collaboration agreement with Switzerland's ClearideBio for the MRX-23 project. The nominal cap on milestone payments for the development, registration, and sales of MRX-23 totals 223 million US dollars, while the cap for all platform collaboration projects, if all options are exercised and all milestones are achieved, totals 750 million US dollars. Under the agreement, an upfront payment of 1 million US dollars is payable as agreed after the agreement takes effect and is non-refundable, and near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. Biwin Storage Technology announced that as of September 30, 2026, it had cumulatively repurchased 1,044,700 shares, accounting for 0.22 percent of total share capital, with a total payment of 222 million yuan. The repurchase plan is expected to involve a total amount of 200 million to 250 million yuan. Sino Medical Sciences Technology's coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. Jiangsu Jindike Biotechnology's trivalent influenza vaccine has obtained a drug registration certificate, but the company expects full-year revenue may fall below 100 million yuan and it will not be able to turn a profit. If it triggers the financial delisting risk warning conditions, the Shanghai Stock Exchange will impose a delisting risk warning on the company's shares.

Konruns Pharmaceutical announced on October 9 that as of September 30, 2026, the company had repurchased 2 million shares, accounting for 1.24% of total share capital, with a repurchase amount of 78.43 million yuan and a repurchase price range of 28.36 yuan to 51.4 yuan per share. In the first half of 2026, Konruns Pharmaceutical achieved revenue of 463 million yuan and net profit attributable to the parent of 95.72 million yuan.

Olymvax Biopharmaceuticals disclosed a litigation progress announcement on the evening of October 9. The first-instance judgment in a technology transfer contract dispute has been served. The court found the plaintiff to be in breach of contract, and the listed company's core claim to terminate the contract was upheld. The case stems from a Technology Transfer Contract signed on June 22, 2011. Plaintiff Wang Jianhua filed suit in December 2025, claiming product royalties and liquidated damages totaling 19.2 million yuan, which was amended to 20.88 million yuan in January 2026. The company subsequently filed a counterclaim, seeking confirmation of contract termination and demanding a refund of the price plus liquidated damages totaling 9.7 million yuan. The court found that the plaintiff failed to fully perform contractual obligations and constituted a breach, and that the contract was terminated on January 27, 2026. It ordered the company to pay the plaintiff 2 million yuan and the plaintiff to pay the company 1 million yuan in liquidated damages. After offsetting the two amounts, the company's actual net burden is 1 million yuan. Of the plaintiff's 20.88 million yuan claim, the 2 million yuan awarded is less than one-tenth of the amount sought. The company's full-year 2025 revenue was 704 million yuan and net profit attributable to the parent was 22.2601 million yuan. The 1 million yuan net expense has limited impact on current-period profit and loss, but the case is still within the appeal period and the first-instance judgment has not yet taken effect. On the operational side, the company achieved revenue of 361 million yuan in the first half of 2026, up 18.14 percent year on year. Affected by factors including back taxes, net profit attributable to the parent was negative 32.8726 million yuan, swinging from profit to loss year on year. Its recombinant Staphylococcus aureus vaccine completed unblinding of the Phase III clinical trial in July 2026, with protective efficacy reaching 73.25 percent, exceeding the pre-specified 60 percent target, making it the world's first Staphylococcus aureus vaccine to complete Phase III clinical trials. The company aims to formally file for production approval before the end of 2026.

Shanghai RAAS disclosed the latest progress of its share repurchase on October 9. As of September 30, 2026, the company had repurchased a total of 17.0032 million shares through a dedicated securities account for share repurchases by centralized bidding, accounting for 0.258% of the company's total share capital. The highest transaction price in this repurchase was 5.12 yuan per share, and the lowest was 4.93 yuan per share. The total transaction amount was about 85.6859 million yuan, excluding transaction costs such as trading commissions.

Sionna Therapeutics announced it will present new data on its NBD1 stabilizers at the 2026 North American Cystic Fibrosis Conference in Atlanta, Georgia, held October 7-10, 2026. The oral presentation covers previously disclosed post hoc analyses of the PreciSION CF Phase 2a trial of SION-719 added to Trikafta; although the trial missed its key activity endpoint, analyses excluding three participants with PK patterns consistent with dosing non-adherence showed a mean placebo-adjusted sweat chloride reduction of 8.6 mmol/L, and identified lower exposures of all three Trikafta components plus a potential interaction between SION-719 and the potentiator ivacaftor. Sionna said these findings, together with favorable Phase 1 safety, tolerability and PK results, support advancing SION-451 plus SION-2222 into AscenSION CF, an open-label, 28-day Phase 2a proof-of-concept trial assessing sweat chloride, safety and PK in adults with CF homozygous for F508del, expected to begin in the first quarter of 2027. A poster presents preclinical data showing that NBD1 stabilizers SION-451 and SION-719, in combination with complementary modulators including SION-2222 and SION-109, improved CFTR trafficking and function up to wild-type levels across primary human bronchial epithelial cells from F508del/F508del and F508del/null donors, supporting their potential to benefit a broad population of people with CF.

Vaxcyte has raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate. The financing came after the Phase 3 OPUS 1 readout, and the company's shares have traded at US$66.96, with a 7 day share price return of 17.68% and a year to date share price gain of 44.12%. The 1 year total shareholder return of 64.36% and 5 year total shareholder return of 175.56% reflect momentum reinforced by the OPUS 1 update and the US$1b mix of equity and convertible note financing completed this week. Vaxcyte is currently trading at 3.6x book value, compared with 2x for the wider US Biotechs group and 9.3x for closer peers, while a widely followed narrative framework anchors fair value closer to $75 using a 7.51% discount rate. Completion of a dedicated large scale manufacturing facility with Lonza, build out of a high volume fill finish line in North Carolina and plans to build commercial supply ahead of a possible VAX-31 launch could support stronger net margins, though OPUS-2 or OPUS-3 data or higher than modeled manufacturing costs could reset expectations.

Editas Medicine traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company's gene-editing therapy EDIT-401, and Wells Fargo upgraded the biotech to Overweight from Equal Weight in reaction. The Cambridge, Massachusetts-based company said the Human Research Ethics Committee of Australia approved the initiation of its Phase 1/2 Strive trial for EDIT-401 in patients with hyperlipidemia. Strive is designed to test a single dose of the in vivo gene editing medicine in heterozygous familial hypercholesterolemia, a genetic disorder characterized by high levels of low-density lipoprotein cholesterol, also known as bad cholesterol. Wells Fargo analyst Yanan Zhu called the initiation of what the company described as the first-in-human clinical trial of EDIT-401 a key step towards unlocking a highly differentiated LDL-C approach, and raised his price target on the stock to $6 from $4, reflecting revised probability of success assumptions for EDIT-401. Initial safety and tolerability data from Strive are expected in Q1 2027, ahead of topline safety and efficacy data from Part 1 of the study anticipated later that year.

Madrigal Pharmaceuticals drew fresh attention after publishing a secondary analysis of its Phase 3 MAESTRO-NASH trial, indicating that Rezdiffra's liver benefits appeared consistent across several common MASH genetic risk variants. The company's shares have eased in recent months, down 9.86% on a 30 day basis and 17.87% year to date, though the 1 year total shareholder return of 11.62% and a 5 year total shareholder return near 6x suggest longer term momentum has remained strong. Madrigal last closed at $487.72, while the most widely followed fair value narrative sits higher at $678.71 based on a 7.16% discount rate, a gap that keeps attention on how Rezdiffra and its MASH footprint could support the valuation story. The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity. The story could still change quickly if Rezdiffra underwhelms in later stage data, or if rivals and payer pushback squeeze long term uptake.

AbbVie announced that the FDA has granted two Breakthrough Therapy designations to its investigational next-generation antibody-drug conjugate telisotuzumab adizutecan, known as Temab-A or ABBV-400, for two different cancer indications: colorectal cancer and non-small cell lung cancer. One designation covers Temab-A in combination with bevacizumab for adults with refractory, metastatic colorectal cancer previously treated with fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and, if indicated, anti-EGFR monoclonal antibody therapy. The second designation is for Temab-A as a monotherapy in adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous non-small cell lung cancer who previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody therapy. The two new designations mark the first Breakthrough Therapy designations for Temab-A, and both were based on data from the first-in-human M21-404 study. AbbVie is also evaluating Temab-A in other advanced solid tumors, including head and neck squamous cell carcinoma, gastroesophageal adenocarcinoma, pancreatic ductal adenocarcinoma and ovarian cancer, through a development program that includes several phase III and phase II/III studies.